Literature DB >> 1522482

Evaluation of hypothesis testing for comparing two populations using NONMEM analysis.

D B White1, C A Walawander, D Y Liu, T H Grasela.   

Abstract

In a simulation study of inference on population pharmacokinetic parameters, two methods of performing tests of hypotheses comparing two populations using NONMEM were evaluated. These two methods are the test based upon 95% confidence intervals and the likelihood ratio test. Data were simulated according to a monoexponential model and, in that context, power curves for each test were generated for (i) the ratio of mean clearance and (ii) the ratio of the population standard deviations of clearance. To generate the power curves, a range of these parameters was employed; other pharmacokinetic parameters were selected to reflect the variability typically present in a Phase II clinical trial. For tests comparing the means, the confidence interval tests had approximately the same power as the likelihood ratio tests and were consistently more faithful to the nominal level of significance. For comparison of the standard deviations, and when the volume of information available was relatively small, however, the likelihood ratio test was more able to detect differences between the two groups. These results were then compared to results on parameter estimation in order to gain insight into the question of power. As an example, the nonnormality of estimates of the ratio of standard deviations plays an important role in explaining the low power for the confidence interval tests. We conclude that, except for the situation of modeling standard deviations with only sparse information, NONMEM produces tests of significance that are effective at detecting clinically significant differences between two populations.

Mesh:

Year:  1992        PMID: 1522482     DOI: 10.1007/bf01062529

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  8 in total

1.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction.

Authors:  T H Grasela; E J Antal; L Ereshefsky; B G Wells; R L Evans; R B Smith
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

4.  A note on confidence intervals with extended least squares parameter estimates.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

5.  Population pharmacokinetic analysis of bisoprolol.

Authors:  J Grevel; P Thomas; B Whiting
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

6.  Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations.

Authors:  K Fattinger; S Vozeh; A Olafsson; J Vlcek; M Wenk; F Follath
Journal:  Clin Pharmacol Ther       Date:  1991-07       Impact factor: 6.875

7.  Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials.

Authors:  N M Graves; T M Ludden; G B Holmes; R H Fuerst; I E Leppik
Journal:  Pharmacotherapy       Date:  1989       Impact factor: 4.705

8.  Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models.

Authors:  M S Driscoll; T M Ludden; D T Casto; L C Littlefield
Journal:  J Pharmacokinet Biopharm       Date:  1989-04
  8 in total
  17 in total

1.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

2.  Design and power of a population pharmacokinetic study.

Authors:  P I Lee
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

3.  Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.

Authors:  Camille Vong; Martin Bergstrand; Joakim Nyberg; Mats O Karlsson
Journal:  AAPS J       Date:  2012-02-17       Impact factor: 4.009

4.  Saturable absorption of sorafenib in patients with solid tumors: a population model.

Authors:  Marilyne Hornecker; Benoit Blanchet; Bertrand Billemont; Hind Sassi; Stanislas Ropert; Fabrice Taieb; Olivier Mir; Halim Abbas; Laura Harcouet; Romain Coriat; Alain Dauphin; François Goldwasser; Michel Tod
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

5.  Model based design and analysis of phase II HIV-1 trials.

Authors:  Dinko Rekić; Daniel Röshammar; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-07-11       Impact factor: 2.745

6.  Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.

Authors:  Julie Bertrand; Emmanuelle Comets; Céline M Laffont; Marylore Chenel; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-27       Impact factor: 2.745

7.  How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  Eur J Clin Pharmacol       Date:  2008-05-16       Impact factor: 2.953

8.  Analysis of the pharmacokinetic interaction between cephalexin and quinapril by a nonlinear mixed-effect model.

Authors:  C Padoin; M Tod; G Perret; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.

Authors:  M Tod; O Lortholary; D Seytre; R Semaoun; B Uzzan; L Guillevin; P Casassus; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

10.  Evaluation of Approaches to Deal with Low-Frequency Nuisance Covariates in Population Pharmacokinetic Analyses.

Authors:  Chakradhar V Lagishetty; Stephen B Duffull
Journal:  AAPS J       Date:  2015-06-26       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.